‘Lack of Substantial Evidence’ Leads to FDA Rejection of Aldeyra Dry Eye Disease Drug

Frank Vinluan / medcitynews - Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye dr…

AI Summary: The FDA has rejected Aldeyra’s reproxalap application, citing a lack of substantial evidence—marking the company’s third setback. Regulators did not demand a fresh, large trial but flagged inconsistent results, prompting investor angst and a slide in the stock. The decision underscores the gap between hopeful early data and regulatory standards.

'Leaky' brain barrier revealed as driver of chronic brain damage in retired combat and collision sports athletes

medicalxpress - Research, led by teams at Trinity College Dublin and the FutureNeuro Research Ireland Center, has pinpointed the mechanism linking some sports injuries to poor brain health in retired athletes. The research, published in Science Translational Medicine, ha…

AI Summary: New research links repetitive head impacts in contact and combat sports to blood–brain barrier breakdown, which appears to drive chronic traumatic encephalopathy and progressive cognitive decline. The studies identify vascular leakage as a key mechanism and suggest that strategies to bolster the barrier could reduce long-term brain damage in athletes and veterans.